Trent J F, Kirsner R S
Department of Dermatology, University of Miami School of Medicine, Florida 33136, USA.
Int J Clin Pract. 1998 Sep;52(6):408-13.
Driven by the need for a readily available, non-immunological tissue that possesses many of the characteristics of normal human skin, tissue-engineered skin has been developed. For over a decade, laboratory grown or processed skin has been under investigation and, in some cases, available as an alternative to autologous grafts. Apligraf, derived from neonatal foreskin and bovine type I collagen, is the first bi-layered living skin equivalent approved in the US and other countries for use in venous ulcers. Apligraf is effective both in the treatment of refractory venous ulcers and for acute wounds such as surgical excision sites and split thickness donor sites. Apligraf is safe and is not clinically rejected. Its ultimate fate is not known, so it may well work to aid healing in a variety of ways including graft 'take' and as a stimulus for healing.
由于需要一种易于获得、非免疫性且具备许多正常人皮肤特征的组织，组织工程皮肤应运而生。十多年来，实验室培养或加工的皮肤一直在研究中，在某些情况下，可作为自体移植的替代物。Apligraf源自新生儿包皮和牛I型胶原蛋白，是美国和其他国家批准用于静脉溃疡治疗的首个双层活性皮肤替代物。Apligraf在治疗难治性静脉溃疡以及手术切除部位和中厚皮片供皮区等急性伤口方面均有效。Apligraf安全且不会被临床排斥。其最终去向尚不清楚，因此它很可能通过多种方式促进愈合，包括移植“存活”以及作为愈合刺激物。
